Olema Pharmaceuticals (OLMA): Price and Financial Metrics

Olema Pharmaceuticals (OLMA): $10.00

0.71 (-6.63%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

Add OLMA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#298 of 363

in industry

OLMA Price/Volume Stats

Current price $10.00 52-week high $17.79
Prev. close $10.71 52-week low $3.64
Day low $9.91 Volume 205,464
Day high $10.76 Avg. volume 779,977
50-day MA $12.61 Dividend yield N/A
200-day MA $12.10 Market Cap 559.15M

OLMA Stock Price Chart Interactive Chart >


Olema Pharmaceuticals (OLMA) Company Bio


Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.


OLMA Latest News Stream


Event/Time News Detail
Loading, please wait...

OLMA Latest Social Stream


Loading social stream, please wait...

View Full OLMA Social Stream

Latest OLMA News From Around the Web

Below are the latest news stories about OLEMA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate OLMA as an investment opportunity.

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

Palazestrant (OP-1250) in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile consistent with the FDA-approved labels of ribociclib or palbociclib plus an endocrine therapyOPERA-01 trials-in-progress poster outlines Phase 3 trial design; clinical sites activated and enrolling with first patient dosed in November 2023Olema will host an investor conference call at 8:00 a.m. ET

Yahoo | December 5, 2023

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company granted stock options to three new employees to purchase an aggregate of 57,500 shares of the Company's common stock, effective as of December 1, 2023. These awards were approved by the Compensation

Yahoo | December 4, 2023

Top Stocks for December 2023

The top stocks have the performance of well-run companies, a steady performance, and the potential for future growth. In addition, top stocks turn over more shares and thus have plenty of liquidity to reduce your transaction costs. Investors often compare top stocks against the Russell 3000 Index, a broad measure of the U.S. stock market comprising 3,000 large publicly traded companies or 96% of the investable U.S. equity market.

Yahoo | December 1, 2023

Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)

Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with palbociclib, and the OPERA-01 Phase 3 clinical trial in progress will be presented on Dec. 7, 2023 Olema will host an investor conference call at 8:00 a.m. ET on Dec. 8, 2023 SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical

Yahoo | November 28, 2023

Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why

Olema's (OLMA) shares surge on the successful development of its lead candidate in metastatic breast cancer indication.

Yahoo | November 27, 2023

Read More 'OLMA' Stories Here

OLMA Price Returns

1-mo -13.42%
3-mo -11.35%
6-mo -5.57%
1-year 150.00%
3-year -71.16%
5-year N/A
YTD -28.72%
2023 472.65%
2022 -73.82%
2021 -80.53%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!